Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression

International Journal of Psychiatry in Clinical Practice

Volumn 18, Issue 2, 2014, Pages 97-102

  Chiesa, Alberto ^a,b   Lia, Loredana ^a   Alberti, Siegfried ^a   Lee, Soo Jung ^c   Han, Changsu ^d   Patkar, Ashwin A ^e   Pae, Chi Un ^c,e   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c The Catholic University of Korea   (South Korea)

^d Korea University   (South Korea)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antidepressants; COMT; DRD2; Epistasis; Major depression; Response

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; PAROXETINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; COMT PROTEIN, HUMAN; CYCLOHEXANOL DERIVATIVE; DRD2 PROTEIN, HUMAN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DSM-IV; FEMALE; GENE FREQUENCY; GENOTYPE; HAMILTON SCALE; HOSPITAL PATIENT; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SAMPLE SIZE; TREATMENT RESPONSE; DEPRESSIVE DISORDER, MAJOR; EPIDEMIOLOGY; EPISTASIS; GENETICS; MIDDLE AGED; SOUTH KOREA; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CATECHOL O-METHYLTRANSFERASE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; EPISTASIS, GENETIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; RECEPTORS, DOPAMINE D2; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 84901460562     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2014.894073     Document Type: Article

References (37)

1. Abou Jamra R, Becker T, Georgi A, Feulner T, Schumacher J, Stromaier J, et al. 2008. Genetic variation of the FAT gene at 4q35 is associated with bipolar affective disorder. Mol Psychiatry 13: 277-284. (Pubitemid 351272659)
2. Andrews JM, Ninan PT, Nemeroff CB. 1996. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 4: 48-56. (Pubitemid 27099509)
3. Arias B, Serretti A, Lorenzi C, Gastó C, Catalán R, Fañanás L. 2006. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 90:251-256. (Pubitemid 43185979)
4. Badner JA, Gershon ES. 2002. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7: 405-411. (Pubitemid 34499362)
5. Baune BT, Hohoff C, Berger K, Neumann A, Mortensen S, Roehrs T, et al. 2008. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 33:924-932. (Pubitemid 351252697)
6. Belmaker RH, Agam G. 2008. Major depressive disorder. N Engl J Med 358:55-68.
7. Carlborg O, Haley CS. 2004. Epistasis: too often neglected in complex trait studies? Nat Rev Genet 5:618-625. (Pubitemid 39005756)
8. Cohen J. 1988. Statistical power analysis for the behavioral sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates.
9. Cusin C, Serretti A, Lattuada E, Lilli R, Lorenzi C, Smeraldi E. 2002. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. Am J Med Genet 114:380-390. (Pubitemid 34525235)
10. Dechant KL, Clissold SP. 1991. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41:225-253.
11. Gvozdic K, Brandl EJ, Taylor DL, Müller DJ. 2012. Genetics and personalized medicine in antidepressant treatment. Curr Pharm Des 18:5853-5878.
12. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Hashimoto R, Okada T, Kato T, Kosuga A, Tatsumi M, Kamijima K, Kunugi H. 2005. The breakpoint cluster region gene on chromosome 22q11 is associated with bipolar disorder. Biol Psychiatry 57:1097-1102. (Pubitemid 40615770)
14. Illi A, Setala-Soikkeli E, Kampman O, Viikki M, Nuolivirta T, Poutanen O, et al. 2010. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Res 176:85-87.
15. Karhunen T, Tilgmann C, Ulmanen I, Panula P. 1995. Catechol-O- methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci Lett 187:57-60.
16. Kato M, Serretti A. 2008. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473-500.
17. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. 2003. The epidemiology of major depressive disorder: results from the national comorbidiy survey replication (NCS-R). JAMA 289:3095-3105. (Pubitemid 37432885)
18. Kind P. 1996. The EuroQoL instrument: an index of health-related quality of life. Quality of life and pharmacoeconomics in clinical trials. B. Spilker. Philadelphia (PA): Lippincott-Raven Publishers, pp. 191-201.
19. Kocabas NA, Faghel C, Barreto M, Kasper S, Linotte S, Mendlewicz J, et al. 2010. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int Clin Psychopharmacol 25:218-227.
20. Koks S, Nikopensius T, Koido K, Maron E, Altmäe S, Heinaste E, et al. 2006. Analysis of SNP profiles in patients with major depressive disorder. Int J Neuropsychopharmacol 9:167-174. (Pubitemid 43255830)
21. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, et al. 1996. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 67:468-472.
22. Massat I, Kocabas NA, Crisafulli C, Chiesa A, Calati R, Linotte S, et al. 2011. COMT and age at onset in mood disorders: A replication and extension study. Neurosci Lett 498:218-221.
23. Massat I, Souery D, Del-Favero J, Nothen M, Blackwood D, Muir W, et al. 2005. Association between COMT (Val(158)Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry 10:598-605. (Pubitemid 40897044)
24. Ohara K, Nagai M, Suzuki Y, Ohara K. 1998. Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport 9:1305-1308. (Pubitemid 28264240)
25. Phillips PC. 2008. Epistasis-the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 9:855-867.
26. Riedel M, Moller HJ, Obermeier M, Schennach-Wolff R, Bauer M, Adli M, et al. 2010. Response and remission criteria in major depression-A validation of current practice. J Psychiatr Res 44:1063-1068.
27. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, et al. 2009. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301:2462-2471.
28. Segurado R, Bellgrove MA, Manconi F, Gill M, Hawi Z. 2011. Epistasis between neurochemical gene polymorphisms and risk for ADHD. Eur J Hum Genet 19:577-582.
29. Serretti A, Chiesa A. 2012. The challenge of uncovering the genetics of anxiety: An editorial comment to Arias B, Aguilera M, Moya J et al. 'The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxiety-related traits'(2). Acta Psychiatr Scand 125:185-186.
30. Serretti A, Rotondo A, Lorenzi C, Smeraldi E, Cassano GB. 2006. Catechol-O-methyltransferase gene variants in mood disorders in the Italian population. Psychiatr Genet 16:181-182. (Pubitemid 44401254)
31. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22-33;quiz 34-57. (Pubitemid 29001829)
32. StatSoft I. 1995. STATISTICA per Windows. Tulsa, OK: StatSoft.
33. Szegedi A, Rujescu D, Tadic A, Müller MJ, Kohnen R, Stassen HH, Dahmen N. 2005. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 5:49-53. (Pubitemid 40220617)
34. van Munster BC, de Rooij SE, Yazdanpanah M, Tienari PJ, Pitkälä KH, Osse RJ, et al. 2010. The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a metaanalysis. Am J Med Genet B Neuropsychiatr Genet 153B:648-655.
35. Wang Y, Liu X, Yu Y, Han Y, Wei J, Collier D, et al. 2012. The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment. Psychiatry Res 200:1047-1050.
36. Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, Li L. 2011. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord 133:165-173.
37. Zimmerman M, Mattia JI, Posternak MA. 2002. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 159: 469-473. (Pubitemid 34184745)